{"id":{"repo_id":"rowan","oai_identifier":"oai:rdw.rowan.edu:etd-4327"},"canonical_url":"https://search.ndltd.org/etd/rowan/oai:rdw.rowan.edu:etd-4327","repository":{"repo_id":"rowan","name":"Rowan University","base_url":"https://rdw.rowan.edu/do/oai/"},"display":{"title":"Novel Synthetic Circuits for Cellular Theranostic Applications","abstract":"Cancer is a complex disease that leads to over 600,000 deaths in the United States each year. Immunoengineering, the process of harnessing a patient's immune system to treat disease, has proven to be a promising therapeutic approach for cancer. For example, the FDA has approved seven chimeric antigen receptor T-cell (CAR-T) therapies. However, these therapies address less than 11% of cancers diagnosed in the United States. In this work, we develop innovative tools to enhance immunoengineering and the efficacy of cell therapies like CAR-T. We introduce and validate synthetic phosphorylation networks with fluorescent and luminescent extension (SPN-FLUX), a synthetic receptor applicable to both immunoengineering and broader synthetic biology tools. We modify SPN-FLUX to function as a biosensor for hypoxia in the tumor microenvironment, an intrinsic feature of nearly all solid cancers and investigate whether we can exploit the native dynamics of hypoxia as a mechanism for cellular therapies to discriminate between healthy and cancerous tissues. Finally, we begin to translate the techniques used in synthetic receptor and biosensor development into computational methodologies. Using computational modeling and docking software, we generate predictions that align with the experimentally obtained preclinical data that were utilized to initiate the Brainchild-01 clinical trial, thereby demonstrating the exciting potential for this in-silico methodology to accelerate the development of life-saving therapies.","abstract_html":"Cancer is a complex disease that leads to over 600,000 deaths in the United States each year. Immunoengineering, the process of harnessing a patient&#x27;s immune system to treat disease, has proven to be a promising therapeutic approach for cancer. For example, the FDA has approved seven chimeric antigen receptor T-cell (CAR-T) therapies. However, these therapies address less than 11% of cancers diagnosed in the United States. In this work, we develop innovative tools to enhance immunoengineering and the efficacy of cell therapies like CAR-T. We introduce and validate synthetic phosphorylation networks with fluorescent and luminescent extension (SPN-FLUX), a synthetic receptor applicable to both immunoengineering and broader synthetic biology tools. We modify SPN-FLUX to function as a biosensor for hypoxia in the tumor microenvironment, an intrinsic feature of nearly all solid cancers and investigate whether we can exploit the native dynamics of hypoxia as a mechanism for cellular therapies to discriminate between healthy and cancerous tissues. Finally, we begin to translate the techniques used in synthetic receptor and biosensor development into computational methodologies. Using computational modeling and docking software, we generate predictions that align with the experimentally obtained preclinical data that were utilized to initiate the Brainchild-01 clinical trial, thereby demonstrating the exciting potential for this in-silico methodology to accelerate the development of life-saving therapies.","abstract_has_math":false,"creators":["Davis, Leah Nicole"],"institution":null,"degree_name":"Doctor of Philosophy (Ph.D.)","degree_level":"Dissertation","degree_discipline":"Biomedical Engineering","degree_department":null,"school":null,"contributors":["Mary Staehle, PhD","Joshua Leonard","Mary Alpaugh"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-11-19T08:59:52Z","subjects":["Biosensor;Immunoengineering;Synthetic Biology;Theranostics"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://rdw.rowan.edu/etd/3321","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://rdw.rowan.edu/etd/3321","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://rdw.rowan.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Ardw.rowan.edu%3Aetd-4327","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Mary Staehle, PhD","Joshua Leonard","Mary Alpaugh"]},{"key":"dc:creator","label":"Author","values":["Davis, Leah Nicole"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2026-02-05T08:00:00Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2025-01-09T08:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Biomedical Engineering"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy (Ph.D.)"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Biosensor;Immunoengineering;Synthetic Biology;Theranostics"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://rdw.rowan.edu/etd/3321"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Cancer is a complex disease that leads to over 600,000 deaths in the United States each year. Immunoengineering, the process of harnessing a patient's immune system to treat disease, has proven to be a promising therapeutic approach for cancer. For example, the FDA has approved seven chimeric antigen receptor T-cell (CAR-T) therapies. However, these therapies address less than 11% of cancers diagnosed in the United States. In this work, we develop innovative tools to enhance immunoengineering and the efficacy of cell therapies like CAR-T. We introduce and validate synthetic phosphorylation networks with fluorescent and luminescent extension (SPN-FLUX), a synthetic receptor applicable to both immunoengineering and broader synthetic biology tools. We modify SPN-FLUX to function as a biosensor for hypoxia in the tumor microenvironment, an intrinsic feature of nearly all solid cancers and investigate whether we can exploit the native dynamics of hypoxia as a mechanism for cellular therapies to discriminate between healthy and cancerous tissues. Finally, we begin to translate the techniques used in synthetic receptor and biosensor development into computational methodologies. Using computational modeling and docking software, we generate predictions that align with the experimentally obtained preclinical data that were utilized to initiate the Brainchild-01 clinical trial, thereby demonstrating the exciting potential for this in-silico methodology to accelerate the development of life-saving therapies."]},{"key":"dc:title","label":"Title","values":["Novel Synthetic Circuits for Cellular Theranostic Applications"]}]}],"canonical_facts":{"dc:contributor":["Mary Staehle, PhD","Joshua Leonard","Mary Alpaugh"],"dc:creator":["Davis, Leah Nicole"],"dc:date.available":["2026-02-05T08:00:00Z"],"dc:date.created":["2025-01-09T08:00:00Z"],"dc:description.abstract":["Cancer is a complex disease that leads to over 600,000 deaths in the United States each year. Immunoengineering, the process of harnessing a patient's immune system to treat disease, has proven to be a promising therapeutic approach for cancer. For example, the FDA has approved seven chimeric antigen receptor T-cell (CAR-T) therapies. However, these therapies address less than 11% of cancers diagnosed in the United States. In this work, we develop innovative tools to enhance immunoengineering and the efficacy of cell therapies like CAR-T. We introduce and validate synthetic phosphorylation networks with fluorescent and luminescent extension (SPN-FLUX), a synthetic receptor applicable to both immunoengineering and broader synthetic biology tools. We modify SPN-FLUX to function as a biosensor for hypoxia in the tumor microenvironment, an intrinsic feature of nearly all solid cancers and investigate whether we can exploit the native dynamics of hypoxia as a mechanism for cellular therapies to discriminate between healthy and cancerous tissues. Finally, we begin to translate the techniques used in synthetic receptor and biosensor development into computational methodologies. Using computational modeling and docking software, we generate predictions that align with the experimentally obtained preclinical data that were utilized to initiate the Brainchild-01 clinical trial, thereby demonstrating the exciting potential for this in-silico methodology to accelerate the development of life-saving therapies."],"dc:identifier":["https://rdw.rowan.edu/etd/3321"],"dc:subject":["Biosensor;Immunoengineering;Synthetic Biology;Theranostics"],"dc:title":["Novel Synthetic Circuits for Cellular Theranostic Applications"],"thesis:degree_discipline":["Biomedical Engineering"],"thesis:degree_level":["Dissertation"],"thesis:degree_name":["Doctor of Philosophy (Ph.D.)"]},"updated_at":"2026-11-19T08:59:52Z"}